6-Aminonicotinamide
mRNA synthesis
In vitro transcription of capped mRNA with modified nucleotides and Poly(A) tail
Tyramide Signal Amplification (TSA)
TSA (Tyramide Signal Amplification), used for signal amplification of ISH, IHC and IC etc.
Phos Binding Reagent Acrylamide
Separation of phosphorylated and non-phosphorylated proteins without phospho-specific antibody
Cell Counting Kit-8 (CCK-8)
A convenient and sensitive way for cell proliferation assay and cytotoxicity assay
SYBR Safe DNA Gel Stain
Safe and sensitive stain for visualization of DNA or RNA in agarose or acrylamide gels.
Inhibitor Cocktails
Protect the integrity of proteins from multiple proteases and phosphatases for different applications.
Ki: 0.46 μM
6-Aminonicotinamide is a 6-phosphogluconate dehydrogenase inhibitor.
6-Phosphogluconate dehydrogenase, an enzyme in the pentose phosphate pathway, can produce ribulose 5-phosphate from 6-phosphogluconate. 6-Phosphogluconate dehydrogenase is also an oxidative carboxylase catalyzing the decarboxylating reduction of 6-phosphogluconate into ribulose 5-phosphate in the presence of NADP.
In vitro: 6-Aminonicotinamide could be metabolized to 6-amino-NAD(P+), a competitive inhibitor of NAD(P+)-requiring processes, especially the pentose phosphate pathway enzyme, 6-phosphogluconate dehydrogenase. Moreove, 6-aminonicotinamide as a single agent could cause a significant inhibition of glycolytic flux but had no effect on the pentose phosphate pathway. 31P-NMR studies of perifused RIF-1 cells indicated that 4 h of exposure to 6-aminonicotinamide was enough to cause significant accumulation of 6-phosphogluconate, the substrate for this enzyme [1].
In vivo: The influence of 6-aminonicotinamide on the G-6-P-DH- and 6-PG-DH-levels of the pentose phosphate pathway in the kidney was investigated. Following i.p. administration of 6-aminonicotinamide at 6 mg/kg, the 6-PG-level rose from a value less than 10 nmoles/g to 1000 nmoles/g fresh weight within 24 h. In addition, at the end of the assay, after 7 days, a 6-PG-concentration of about 150 nmoles/g fresh weight was still seen. Moreove, the G-6-P level simultaneously rose with the 6-PG-level to about 150% of the control level and returned to normal on the 5th day [2].
Clinical trial: So far, no clinical study has been conducted.
References:
[1] Street, J. C.,Alfieri, A.A. and Koutcher, J.A. Quantitation of metabolic and radiobiological effects of 6-aminonicotinamide in RIF-1 tumor cells in vitro. Cancer Research 57, 3956-3962 (1997).
[2] Lange, K. and Proft, E.R. Inhibition of the 6-phosphogluconate dehydrogenase in the rat kidney by 6-aminonicotinamide. Naunyn-Schmiedeberg's Archives of Pharmacology 267, 177-180 (1970).
Storage | Store at -20°C |
M.Wt | 137.1 |
Cas No. | 329-89-5 |
Formula | C6H7N3O |
Synonyms | 6-AN,NSC 21206,SR 4388 |
Solubility | insoluble in H2O; insoluble in EtOH; ≥13.7 mg/mL in DMSO |
Chemical Name | 6-amino-3-pyridinecarboxamide |
SDF | Download SDF |
Canonical SMILES | Nc1ccc(cn1)C(=O)N |
运输条件 | 蓝冰运输或根据您的需求运输。 |
一般建议 | 不同厂家不同批次产品溶解度各有差异,仅做参考。若实验所需浓度过大至产品溶解极限,请添加助溶剂助溶或自行调整浓度。溶液形式一般不宜长期储存,请尽快用完。 |
质量控制和MSDS
- 批次: